Delving into the Latest Updates on Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products), recombinant vaccine(Chongqing Zhifei Biological Products)

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Meningococcal Infections

Inactive Indication-

Originator Organization

Chongqing Zhifei Biological Products Co., Ltd.

Active Organization

Chongqing Zhifei Biological Products Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years

Start Date25 Apr 2021

Sponsor / Collaborator-

EUCTR2008-007182-23-GB

/ Not yet recruitingNot ApplicableIIT

A phase 2, open-label study of the safety, tolerability and immunogenicity of a Novartis meningococcal B vaccine when administered at a 0, 2, 6 month schedule and of a single dose of Novartis meningococcal ACWY conjugate vaccine in healthy adults aged 18-65 years. - Phase II MenB and MenACWY adult study

Start Date16 Mar 2010

Sponsor / Collaborator

Environmental Protection Agency

100 Clinical Results associated with Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products)

Login to view more data

100 Translational Medicine associated with Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products)

Login to view more data

100 Patents (Medical) associated with Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products)

Login to view more data

147

Literatures (Medical) associated with Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products)

01 Apr 2025·Vaccine

Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity

Article

Author: Gissi, A ; Marrani, E ; Sardi, I ; Galli, L ; Trapani, S ; Peri, M ; Tintori, V ; Ricci, S ; Indolfi, G ; Tondo, A ; Astorino, V ; Mastrolia, M V ; Lodi, L ; Mollo, A ; Venturini, E ; Lionetti, P ; Azzari, C

BACKGROUNDA recombinant vaccine is approved to prevent herpes zoster (HZ) in adults ≥50 years and immunocompromised individuals ≥19 years. However, in children, the live attenuated vaccine remains the only prevention strategy against varicella zoster virus (VZV), with only one trial evaluating the safety and immunogenicity of GlaxoSmithKline's HZ subunit candidate vaccine in immunocompromised children.OBJECTIVESTo estimate VZV burden in our third level pediatric hospital and identify high-risk pediatric groups for its occurrence and complications to explore the need for an inactivated vaccine.METHODSWe reviewed VZV/HZ hospital discharge codes and positive VZV molecular tests at Meyer Children's Hospital from January 2018 to May 2023. We categorized patients based on their vaccination status as unvaccinated, partially vaccinated (single dose), or fully vaccinated (complete two-dose regimen). 96 controls from the same Departments and period were also included to assess VZV vaccine effectiveness.RESULTSOf 48 patients with VZV (52 % female; median age: 11.6 years [IQR: 7-14.2]), 10 had chickenpox and 38 HZ; 2/48 (4.2 %) received 2 doses of vaccination, 10/48 (20.8 %) were immunized with 1 dose and 36/48 (75 %) were unvaccinated. Immune-related comorbidities were present in 20/48 (42 %) patients, and among those with HZ requiring hospitalization, comorbidities strongly predicted admission (OR 4.71; 95 % CI, 1.23-20.39; p = 0.028). Full vaccination was more frequent in controls (43/96, 45 %) than in cases (2/48, 4.2 %; p < 0.001).CONCLUSIONSIn our cohort, many cases had comorbidities contraindicating the live attenuated vaccine. If proven safe and effective, the recombinant HZ vaccine could offer a preventive option for immunocompromised children ineligible for live viral vaccines.

01 Jan 2025·Methods in Molecular Biology

Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

Article

Author: Hewson, Roger ; Kennedy, Emma ; Dowall, Stuart

One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.

01 Dec 2024·Revue medicale de Liege

[Herpes zoster : vaccination and management of satellite lesions in immunocompromised patients].

Article

Author: Nikkels, Arjen ; Delahaye, Thibaut

Shingles, also termed herpes zoster (HZ), is due to the reactivation of the varicella zoster virus (VZV) in a dorsal root nerve ganglion with an intra-axonal passage of the virus to a predetermined dermatome. The risk of HZ increases with age, as well as the morbidity risks. The most feared complication is post-herpetic neuralgia, defined as persisting pain sensations three months after the resolution of the skin lesions. Those risks are even more important in the immunocompromised patient. Currently a recombinant vaccine against HZ reactivation is available with an excellent safety profile. It has demonstrated a very high vaccine protection achieving 97 % for preventing HZ and its complications. A patient presented severe facial HZ with a large number of HZ satellite lesions disseminated over the entire tegumentum. These satellite lesions are a reliable clinical marker for HZ with a high risk for complications. This case underlines the risk of morbidity in the elderly immunocompromised patient as well the fact that HZ is a vaccine preventable disease, currently reimbursed, but not well-known.

100 Deals associated with Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products)

Login to view more data